Radiation change versus recurrent astrocytoma: Diagnostic utility of the proliferation index?

Eileen H. Bigio, Sarah M. Colvin, Bruce E. Mickey, Charles L. White, Elisabeth J. Rushing

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Differentiation of recurrent glioma from radiation damage can be a challenge to neurologists, neurosurgeons, neuroradiologists, and even neuropathologists. We hypothesized that by evaluating sections of recurrent lesions with proliferation markers we might objectively differentiate between radiation damage gliosis and recurrent astrocytoma. We compared the labeling indices of radiation damage and recurrent neoplasm immunohistochemically, using an antibody to MIB-1, a monoclonal antibody to the Ki-67 proliferation marker. Five of the six recurrent neoplasms were gliomas; four these were astrocytic tumors. In most cases, the MIB-1 LI of radiation damage was < 1% and the LI of recurrent neoplasm was > 3%, with pertinent exceptions. We discuss our findings and their possible interpretation.

Original languageEnglish (US)
Pages (from-to)55-63
Number of pages9
JournalJournal of Neuro-Oncology
Issue number1
StatePublished - 1999


  • Astrocytoma
  • Glioma
  • Ki-67
  • MIB-1
  • Proliferation marker
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Radiation change versus recurrent astrocytoma: Diagnostic utility of the proliferation index?'. Together they form a unique fingerprint.

Cite this